Comprehensive Therapy

, Volume 29, Issue 4, pp 215–223

Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients

  • Sara Jane Andersen
Original Article


Nonsteroidal anti-inflammatory drugs are often prescribed to treat osteoarthritis. Two cyclooxygenase isoenzymes prompted the development selective COX-2 inhibitors. The development, efficacy, and toxicity of COX-2 inhibitor treatment of osteoarthritis are summarized.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rofecoxib (Bioxx) prescribing information. Merck & Co. Whitehouse Station, NJ; 1998. Revised April, 2002.Google Scholar
  2. 2.
    Celecoxib (Celebrex) prescribing information. G.D. Searle & Co.; 1998.Google Scholar
  3. 3.
    Valdecoxib (Bextra) prescribing information; Pharmacia Corp./Pfizer Inc; 2001.Google Scholar
  4. 4.
    Felson DT, Zhang Y, Hannan MT, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1995;38: 1500–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Guccione A, Felson D, Anderson J, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994; 84:351–8.PubMedGoogle Scholar
  6. 6.
    Guccione A, Felson D, Anderson J, et al. Defining arthritis and measuring functional status in elders: Methodological issues in the study of disease and physical disability. Am J Public Health. 1990;80:945–9.PubMedGoogle Scholar
  7. 7.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–99.PubMedCrossRefGoogle Scholar
  8. 8.
    Griffin M, Piper J, Daugherty J, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257–263.PubMedGoogle Scholar
  9. 9.
    Cheatum D, Arvanitakis C, Gumpel M, et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21:992–1003.PubMedCrossRefGoogle Scholar
  10. 10.
    Lichtenstein D, Syngal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum. 1995;38:5–18.PubMedCrossRefGoogle Scholar
  11. 11.
    Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999; 26:18–24.Google Scholar
  12. 12.
    Rahme E, Joseph L, Kong S, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen. Arthritis Rheum. 2000;43:917–924.PubMedCrossRefGoogle Scholar
  13. 13.
    Johnson R, Hornbrook M, Hooker R, et al. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organization. Pharmacoeconomics. 1997; 12:76–88.PubMedGoogle Scholar
  14. 14.
    Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106:13S-24S.PubMedCrossRefGoogle Scholar
  15. 15.
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med. 2000;160:777–784.PubMedCrossRefGoogle Scholar
  16. 16.
    Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106:25S-36S.PubMedCrossRefGoogle Scholar
  17. 17.
    Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology. 1971;231:232–235.PubMedGoogle Scholar
  18. 18.
    Ferreira S, Moncada S, Vane J. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biology. 1971;231:237–239.PubMedCrossRefGoogle Scholar
  19. 19.
    Smith J, Willis A. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biology. 1971; 231:235–237.PubMedCrossRefGoogle Scholar
  20. 20.
    Picot D, Loll P, Garavito R. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994;367:243–249.PubMedCrossRefGoogle Scholar
  21. 21.
    Sirois J, Richards J. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem. 1992; 267:6382–6388.PubMedGoogle Scholar
  22. 22.
    Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996;3:927–933.PubMedCrossRefGoogle Scholar
  23. 23.
    Kraemer S, Meade S, DeWitt D. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys. 1992;293:391–400.PubMedCrossRefGoogle Scholar
  24. 24.
    Fletcher B, Kujubu D, Perrin D, et al. Structure of the mitogen-inducible TIS10 gene and functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338–4344.PubMedGoogle Scholar
  25. 25.
    Crofford L. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997;24:15–19.Google Scholar
  26. 26.
    Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Chan C. Rofecoxib (Vioxx, MK-0966; 4-4′-methylsulfonylphenyl-3-phenyl-2-5H-furanone): A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551–560.PubMedGoogle Scholar
  28. 28.
    Ehrich E, Ballob A, De Lepeleire I, et al. Characterisation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336–347.PubMedCrossRefGoogle Scholar
  29. 29.
    Ehrich E, Schnitzer T, Kivitz A, et al. MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [Abstract]. Arthritis Rheum. 1997;40:S85.Google Scholar
  30. 30.
    Simon L, Lanza F, Lipsky P, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998;41:1591–1602.PubMedCrossRefGoogle Scholar
  31. 31.
    Day R, Morrison B, Luza A, et al. A Randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781–1787.PubMedCrossRefGoogle Scholar
  32. 32.
    Cannon G, Caldwell J, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum. 2000; 43:978–987.PubMedCrossRefGoogle Scholar
  33. 33.
    Saag K, Fisher C, McKay J, et al. MK-0966, A specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial [Abstract]. Arthritis Rheum. 1998; 41:S196.Google Scholar
  34. 34.
    Bensen W, Fiechtner J, McMillen J, Zhao W, et al. Treatment of Osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc. 1999;74:1095–1105.PubMedGoogle Scholar
  35. 35.
    Geba G, Polis A, Dixon M, et al. Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis [Abstract]. Arthritis Rheum. 1999; 42:S144.Google Scholar
  36. 36.
    Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Intern Med Res. 2001;29: 467–479.Google Scholar
  37. 37.
    McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheum. 2001;30:11–18.PubMedCrossRefGoogle Scholar
  38. 38.
    Williams GW, Hubbard RC, Yu SS, et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther. 2001; 23:213–227.PubMedCrossRefGoogle Scholar
  39. 39.
    Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Family Prac. 2002;51:530–537.Google Scholar
  40. 40.
    Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290–296.PubMedCrossRefGoogle Scholar
  41. 41.
    Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee A randomized trial. JAMA. 2002;287:64–71.PubMedCrossRefGoogle Scholar
  42. 42.
    McKenna F, Weaver A, Fiechtner JJ, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled randomized, double-blind study. J Clin Rheum. 2001;7:151–159.CrossRefGoogle Scholar
  43. 43.
    Lanza F, Rack M, Simon T, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999;13:761–767.PubMedCrossRefGoogle Scholar
  44. 44.
    Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational study group. Arthritis Rheum. 2000;43:370–377.PubMedCrossRefGoogle Scholar
  45. 45.
    Langman M, Jensen D, Watson D, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1961–1963.CrossRefGoogle Scholar
  46. 46.
    Watson DJ, Harper SE, Zhao P, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160: 2998–3003.PubMedCrossRefGoogle Scholar
  47. 47.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343: 1520–1528.PubMedCrossRefGoogle Scholar
  48. 48.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA. 2000; 284:1247–1255.PubMedCrossRefGoogle Scholar
  49. 49.
    Schoenfeld P. An evidence-based approach to the gastrointestinal safety profile of COX-2 selective anti-inflammatories. Gastroenterol Clin North Am. 2001;30:1027–1044.PubMedCrossRefGoogle Scholar
  50. 50.
    Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib: novel COX-2 inhibitor. Am J Gastroenterol 2000;95: 1681–1690.PubMedCrossRefGoogle Scholar
  51. 51.
    Goldstein JL, Correa P, Zhao, ww, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019–1027.PubMedCrossRefGoogle Scholar
  52. 52.
    Bensen, WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 Specific Inhibitor, compared to naproxen and placebo. J Rheum. 2000;27: 1876–1883.PubMedGoogle Scholar
  53. 53.
    Swan S, Rudy D, Lasseter K, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000;133:1–9.PubMedGoogle Scholar
  54. 54.
    Catella-Lawson F, Mcadam B, Morrison B, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–741.PubMedGoogle Scholar
  55. 55.
    Daniels B, Gertz B, Morrison B, Seidenberg B. Renal safety profile of rofecoxib, a specific inhibitor of COX-2, in controlled clinical trials. Arthritis Rheum. 1999;42:S143.Google Scholar
  56. 56.
    Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465–70.PubMedCrossRefGoogle Scholar
  57. 57.
    Francis KL, Chan MD, Lawrence CT, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347:2104–2110.CrossRefGoogle Scholar
  58. 58.
    Truitt KE, Sperling RS, Ettinger WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano). 2001;13: 112–121.Google Scholar
  59. 59.
    McAdam B, Catella-Lawson F, Mardini, I, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX-2): The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci 1999;96:272–277.PubMedCrossRefGoogle Scholar
  60. 60.
    Abramowicz M. Rofecoxib for osteoarthritis and pain. The Medical Letter. 1999;41:59–61.Google Scholar
  61. 61.
    Leese PT, Talwalker S, Kent JD, et al. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275–81.PubMedCrossRefGoogle Scholar
  62. 62.
    Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959.PubMedCrossRefGoogle Scholar
  63. 63.
    Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071–1073.PubMedCrossRefGoogle Scholar
  64. 64.
    Reicin AS, Shapiro D Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89:204–209.PubMedCrossRefGoogle Scholar
  65. 65.
    Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280–2288.PubMedGoogle Scholar
  66. 66.
    Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol. 2000;40:655–663.PubMedCrossRefGoogle Scholar
  67. 67.
    Mersfelder T, Stewart L. Warfarin and celecoxib interaction. Ann Pharmacother. 2000;34:325–326.PubMedCrossRefGoogle Scholar
  68. 68.
    Juliano D. Physician Information Regarding rofecoxib. Merck & Co. Inc.; 2000.Google Scholar
  69. 69.
    Truitt K, Ettinger W, Schnitzer T, et al. Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients aged 80 years and older. 14 th Europ League Against Rheum Congr. 1999;1:859.Google Scholar
  70. 70.
    American College of Rheumatology subcommittee on osteoarthritis guidelines: Recommendations for the medical managemental of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905–1915.Google Scholar
  71. 71.
    Bradley J, Brandt K, Katz B, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Williams H, Ward J, Egger J, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196–1206.PubMedCrossRefGoogle Scholar
  73. 73.
    Discusion I: Clinical value of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:21S-22S.CrossRefGoogle Scholar
  74. 74.
    Altman R. The syndrome of osteoarthritis. J Rheumatol. 1997;24:766–767.PubMedGoogle Scholar
  75. 75.
    Bird H. When are NSAIDs appropriate in osteoarthritis? Drugs Aging. 1998;12:87–95.PubMedCrossRefGoogle Scholar
  76. 76.
    Boegard T, Rudling O, Dahlstrom J, et al. Bone scintigraphy in chronic knee pain: Comparison with magnetic resonance imaging. Ann Rheum Dis. 1999;58:20–26.PubMedCrossRefGoogle Scholar
  77. 77.
    Doherty M. Synovial inflammation and osteoarthritis progression: Effects of nonsteroidal antiinflammatory drugs. Osteoarthritis Cartilage. 1999;7:319–320.PubMedCrossRefGoogle Scholar
  78. 78.
    Nakamura H, Yoshino S, Kato T, et al. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage. 1999;7:401–402.PubMedCrossRefGoogle Scholar
  79. 79.
    Walker J, Sheather-Reid R, Carmody J, et al. Nonsteroidal anti-inflammatory drugs in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1997;40:1944–1954.PubMedCrossRefGoogle Scholar
  80. 80.
    Wolfe, F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients. Arthritis Rheum. 2000;43:378–385.PubMedCrossRefGoogle Scholar
  81. 81.
    Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2001;44:1587–1598.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2003

Authors and Affiliations

  • Sara Jane Andersen
    • 2
    • 1
  1. 1.Divisions of Rheumatology and GeriatricsUniversity of UtahSalt Lake City
  2. 2.VA Salt Lake City Health Care SystemSalt Lake CityUSA

Personalised recommendations